Literature DB >> 9653159

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

E Beutler1, T Gelbart, A Demina.   

Abstract

A polymorphism in the promoter of the UDP-glucuronosyltransferase 1 (UGT1A1) gene has been shown to cause Gilbert syndrome, a benign form of unconjugated bilirubinemia. Promoters containing seven thymine adenine (ta) repeats have been found to be less active than the wild-type six repeats, and the serum bilirubin levels of persons homozygous or even heterozygous for seven repeats have been found to be higher than those with the wild-type six repeats. We have now examined the genotypes in persons of Asian, African, and Caucasian ancestry. Although within the Caucasian ethnic group there is a strong correlation between promoter repeat number and bilirubin level, between ethnic groups we found that this relationship to be inverse. Among people of African ancestry there are, in addition to those with six and seven repeats, also persons who have five or eight repeats. Using a reporter gene we show that there is an inverse relationship between the number of ta repeats and the activity of the promoter through the range of 5-8 ta repeats. An incidental finding was a polymorphism at nucleotide -106, tightly linked to the (ta)5 haplotype. Serum bilirubin levels are influenced by many factors, both genetic and environmental. We suggest that the unstable UGT1A1 polymorphism may serve to "fine-tune" the plasma bilirubin level within population groups, maintaining it at a high enough level to provide protection against oxidative damage, but at a level that is sufficiently low to prevent kernicterus in infants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653159      PMCID: PMC20948          DOI: 10.1073/pnas.95.14.8170

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Population studies on Gilbert's syndrome.

Authors:  D Owens; J Evans
Journal:  J Med Genet       Date:  1975-06       Impact factor: 6.318

2.  Studies on the neonatal development of the glucuronide conjugating system.

Authors:  A K BROWN; W W ZUELZER
Journal:  J Clin Invest       Date:  1958-03       Impact factor: 14.808

3.  Ethnic differences in neonatal jaundice: comparison of Japanese and Caucasian newborn infants.

Authors:  T Horiguchi; C Bauer
Journal:  Am J Obstet Gynecol       Date:  1975-01-01       Impact factor: 8.661

4.  Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia.

Authors:  M Kaplan; P Renbaum; E Levy-Lahad; C Hammerman; A Lahad; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

5.  Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults.

Authors:  M Madhavan; W A Wattigney; S R Srinivasan; G S Berenson
Journal:  Atherosclerosis       Date:  1997-05       Impact factor: 5.162

Review 6.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence.

Authors:  P I Mackenzie; I S Owens; B Burchell; K W Bock; A Bairoch; A Bélanger; S Fournel-Gigleux; M Green; D W Hum; T Iyanagi; D Lancet; P Louisot; J Magdalou; J R Chowdhury; J K Ritter; H Schachter; T R Tephly; K F Tipton; D W Nebert
Journal:  Pharmacogenetics       Date:  1997-08

7.  The protective role of bilirubin in oxygen-radical diseases of the preterm infant.

Authors:  T Hegyi; E Goldie; M Hiatt
Journal:  J Perinatol       Date:  1994 Jul-Aug       Impact factor: 2.521

8.  Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome.

Authors:  G Monaghan; M Ryan; R Seddon; R Hume; B Burchell
Journal:  Lancet       Date:  1996-03-02       Impact factor: 79.321

9.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

Authors:  P J Bosma; J R Chowdhury; C Bakker; S Gantla; A de Boer; B A Oostra; D Lindhout; G N Tytgat; P L Jansen; R P Oude Elferink
Journal:  N Engl J Med       Date:  1995-11-02       Impact factor: 91.245

10.  Hyperbilirubinaemia in heterozygous beta-thalassaemia is related to co-inherited Gilbert's syndrome.

Authors:  R Galanello; L Perseu; M A Melis; L Cipollina; S Barella; N Giagu; M P Turco; O Maccioni; A Cao
Journal:  Br J Haematol       Date:  1997-11       Impact factor: 6.998

View more
  186 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study.

Authors:  Jing-Ping Lin; L Adrienne Cupples; Peter W F Wilson; Nancy Heard-Costa; Christopher J O'Donnell
Journal:  Am J Hum Genet       Date:  2003-02-28       Impact factor: 11.025

3.  Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity.

Authors:  Nathan R Jones; Dongxiao Sun; Willard M Freeman; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2012-06-01       Impact factor: 4.030

Review 4.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

5.  Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome.

Authors:  Yoshihiro Maruo; Carlos D'Addario; Asami Mori; Masaru Iwai; Hiroko Takahashi; Hiroshi Sato; Yoshihiro Takeuchi
Journal:  Hum Genet       Date:  2004-09-17       Impact factor: 4.132

6.  Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority.

Authors:  Cynthia Sung; Pui Ling Lee; Liesbet L Tan; Dorothy S L Toh
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

7.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 8.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

9.  Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

Authors:  Eric Lévesque; Anne-Sophie Bélanger; Mario Harvey; Félix Couture; Derek Jonker; Federico Innocenti; Erica Cecchin; Giuseppe Toffoli; Chantal Guillemette
Journal:  J Pharmacol Exp Ther       Date:  2013-02-05       Impact factor: 4.030

10.  Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.

Authors:  Edward P Acosta; Michelle A Kendall; John G Gerber; Beverly Alston-Smith; Susan L Koletar; Andrew R Zolopa; Sangeeta Agarwala; Michael Child; Richard Bertz; Lara Hosey; David W Haas
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.